Tyligand Bioscience Shanghai Limited announced that it has received $20.000000 million in funding from China Medical System Inc., Yijing Capital and another investor.

Tyligand Bioscience (Shanghai) Limited announced that it has received $20,000,000 in funding on May 21, 2021. The transaction included participation from China Medical System Inc., Yijing Capital, and VI Ventures.